Turk Ilac Ve Serum Sanayi Anonim Sirketi Stock

Equities

TRILC

TRETRLC00022

Pharmaceuticals

Market Closed - Borsa Istanbul 11:08:48 2024-05-31 am EDT 5-day change 1st Jan Change
29.22 TRY -1.55% Intraday chart for Turk Ilac Ve Serum Sanayi Anonim Sirketi -2.01% +155.64%
Sales 2022 833M 25.86M Sales 2023 1.91B 59.36M Capitalization 1.85B 57.38M
Net income 2022 66M 2.05M Net income 2023 106M 3.29M EV / Sales 2022 2.95 x
Net Debt 2022 274M 8.49M Net Debt 2023 418M 12.96M EV / Sales 2023 1.19 x
P/E ratio 2022
32.9 x
P/E ratio 2023
17.5 x
Employees 439
Yield 2022 *
-
Yield 2023
-
Free-Float 59.86%
More Fundamentals * Assessed data
Dynamic Chart
Turk Ilac Ve Serum Sanayi Anonim Sirketi Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Turk Ilac Ve Serum Sanayi Anonim Sirketi Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Turk Ilac Ve Serum Sanayi Anonim Sirketi Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Turk Ilac Ve Serum Sanayi Anonim Sirketi Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Turk Ilac Ve Serum Sanayi Anonim Sirketi announces an Equity Buyback for 1,000,000 shares, for TRY 12 million. CI
Turk Ilac Ve Serum Sanayi Anonim Sirketi authorizes a Buyback Plan. CI
Turk Ilac Ve Serum Sanayi Anonim Sirketi Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Turk Ilac Ve Serum Sanayi Anonim Sirketi Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Turk Ilac Ve Serum Sanayi Anonim Sirketi(IBSE:TRILC) dropped from S&P Global BMI Index CI
Turk Ilac Ve Serum Sanayi Anonim Sirketi Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Turk Ilac Ve Serum Sanayi Anonim Sirketi announces an Equity Buyback for 1,000,000 shares, for TRY 12 million. CI
Turk Ilac Ve Serum Sanayi Anonim Sirketi authorizes a Buyback Plan. CI
Turk Ilac Ve Serum Sanayi Anonim Sirketi Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Turk Ilac Ve Serum Sanayi Anonim Sirketi Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Turk Ilac Ve Serum Sanayi Anonim Sirketi Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
More news
1 day-1.55%
1 week-2.01%
1 month+17.82%
3 months+126.86%
6 months+129.72%
Current year+155.64%
More quotes
1 week
26.84
Extreme 26.84
31.74
1 month
24.04
Extreme 24.04
39.18
Current year
11.00
Extreme 11
39.18
1 year
8.74
Extreme 8.74
39.18
3 years
7.81
Extreme 7.81
39.18
5 years
5.24
Extreme 5.2381
39.18
10 years
5.24
Extreme 5.2381
39.18
More quotes
Managers TitleAgeSince
Chief Executive Officer - 21-01-25
Director/Board Member - 19-12-31
Investor Relations Contact - 22-10-31
Members of the board TitleAgeSince
Founder - 10-12-03
Chief Executive Officer - 21-01-25
Director/Board Member 42 19-12-31
More insiders
Date Price Change Volume
24-05-31 29.22 -1.55% 4,947,358
24-05-30 29.68 +4.07% 6,944,327
24-05-29 28.52 -6.61% 11,788,720
24-05-28 30.54 +0.79% 17,693,420
24-05-27 30.3 +1.61% 41,887,010

Delayed Quote Borsa Istanbul, May 31, 2024 at 11:08 am EDT

More quotes
Turk Ilac ve Serum Sanayi AS is a Turkey-based pharmaceutical company. The main activity of the Company is to manufacture and sell all kinds of tablets, capsules, ampoules, vials, ointments-creams, intravenous serums, parenteral solutions, nutritional solutions, amino acids and other chemical substances. The company also acts as the representative or sales agency of other domestic and foreign pharmaceutical companies, as well as importing and marketing veterinary, cosmetics and pesticides. Turk Ilac manufactures in accordance with Current Good Manufacturing (GMP) and Good Laboratory Practice (GLP) principles with its approximately 300 employees in its facilities on a total area of 56.000 square meters in the Ankara - Akyurt region.
More about the company